GeneDx Holdings Corp. has announced the launch of GenomeDx Prenatal™, a new whole genome sequencing (WGS) service designed for prenatal care. This expansion brings industry-leading genomic diagnostics to pregnancies with fetal anomalies identified via ultrasound, enabling faster and more comprehensive diagnosis. GenomeDx Prenatal offers rapid turnaround, robust variant detection, and supports families with postnatal and lifetime reanalysis options. The new service will be available for clinicians to order beginning in February 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107735253) on January 07, 2026, and is solely responsible for the information contained therein.

